Form 4: Blueprint Medicines Director Albers Exercises Options and Sells Shares

Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp on March 12, 2025, according to a Form 4 filing.

Summary

• On March 12, 2025, Jeffrey W. Albers, a director of Blueprint Medicines Corp, exercised stock options to acquire 7,500 shares of common stock at a price of $36.05 per share.
• Simultaneously, Albers sold 5,700 shares at a weighted average price of $87.62 and 1,800 shares at a weighted average price of $88.37.
• These transactions were executed under a pre-arranged trading plan adopted on May 8, 2024, in accordance with Rule 10b5-1.
• Following these transactions, Albers beneficially owns 152,396 shares of Blueprint Medicines Corp.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. Sales by insiders can sometimes be interpreted negatively by the market, but pre-planned sales under Rule 10b5-1 are common and often viewed as less concerning.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates